C.M.R. 10, 144, ch. 258, app A - NOTIFIABLE DISEASES AND CONDITIONS LIST

* Category I Diseases must be reported to the Department immediately.

** Category II Diseases must be reported within 48 hours of the diagnosis or laboratory test result.

# Laboratories are to submit isolates or clinical specimens for the following, as well as any isolates or clinical specimens, as requested by HETL for confirmation, typing and/or antibiotic sensitivity.

Table 1.

Notifiable Diseases and Conditions
Disease or Condition			Agent
**	Acquired immunodeficiency syndrome (AIDS)	Human immunodeficiency virus
**	Acute flaccid myelitis (AFM)1
**	Anaplasmosis	Anaplasmaphagocytophilum
*	#	Anthrax	Bacillus anthracis
**	Babesiosis	Babesia microti
*	#	Botulism	Clostridium botulinum
**	Borrelia miyamotoi	Borrelia miyamotoi
*	#	Brucellosis	Brucella species
**	California serogroup viruses
**	Campylobacteriosis	Campylobacter species
*	#	Candida auris2	Candida auris
*	#	Carbapenemase-producing carbapenem-resistant organisms3	Enterobacteriaceae spp. Pseudomonas aeruginosa (non-mucoid only) Acinetobacter baumannii
**	Carbon monoxide poisoning4	Carbon monoxide
**	Chancroid	Haemophilusducreyi
**	Chlamydia	Chlamydia trachomatis
**	Chickenpox (varicella)	Varicella-zoster virus
**	Chikungunya	Chikungunya virus
*	#	Coronavirus (novel, MERS, and SARS)	Coronavirus
**	Creutzfeldt-Jakob disease, < 55 years of age	Creutzfeldt-Jakob agent
**	Cryptosporidiosis	Cryptosporidium species
**	Cyclosporiasis	Cyclospora
**	Dengue	Dengue fever virus
Disease or Condition	Agent
*	#	Diphtheria	Corynebacterium diphtheriae
**	#	E.coli, Shiga toxin-producing (STEC)	Escherichia coli, Shiga toxin-producing
**	Eastern equine encephalitis	Eastern equine encephalitis virus
**	Ehrlichiosis	Ehrlichiaspecies
**	Giardiasis	Giardia species
**	Gonorrhea	Neisseria gonorrhoeae
**	#	Haemophilus influenzae,invasive	Haemophilus influenzae
**	Hantavirus, pulmonary and non-pulmonary syndromes	Hantavirus
**	Hemolytic-uremic syndrome (post-diarrheal)	Escherichia coli, Shiga toxin-producing
*	Hepatitis A, B, C, D, E (acute)	Hepatitis A, B, C, D, E viruses
**	Hepatitis B, C, D (chronic)	Hepatitis B, C, D viruses
**	Human immunodeficiency virus (HIV)5	Human immunodeficiency virus
**	Influenza-associated pediatric death	Influenza virus
*	#	Influenza A, novel	Influenza virus
**	Influenza-associated hospitalizations, laboratory-confirmed	Influenza virus
**	Legionellosis	Legionella species
**	Leptospirosis	Leptospira species
**	#	Listeriosis	Listeria monocytogenes
**	Lyme disease	Borrelia burgdorferi
**	Malaria	Plasmodium species
*	#	Measles	Rubeola virus
*	#	Meningococcal disease, invasive	Neisseria meningitidis
*	#	Mumps	Mumps virus
*	Pertussis	Bordetella pertussis
*	#	Plague	Yersinia pestis
*	#	Poliomyelitis	Poliovirus
**	Powassan	Powassan or deer tick virus
**	Psittacosis	Chlamydia psittaci
*	Q fever	Coxiella burnetii
*	#	Rabies (human and animal)	Rabies virus
**	Rabies post-exposure prophylaxis
*	#	Ricin poisoning
*	#	Rubella (including congenital)	Rubella virus
**	#	Salmonellosis	Salmonella species
*	Shellfish poisoning
**	#	Shigellosis	Shigella species
*	#	Smallpox	Variola virus
**	Spotted fever rickettsiosis	Rickettsia rickettsii
Disease or Condition	Agent
**	St. Louis encephalitis	St. Louis encephalitis virus
*	#	Staphylococcus aureus non-susceptible to vancomycin6	Staphylococcus aureus
**	Streptococcus group A, invasive	Streptococcus pyogenes (group A beta hemolytic strep)
**	Streptococcus pneumoniae, invasive	Streptococcus pneumoniae
**	Syphilis	Treponema pallidum
*	#	Tetanus	Clostridium tetani
**	Trichinosis	Trichinella species
*	#	Tuberculosis (active and presumptive)	Mycobacterium tuberculosis
*	#	Tularemia	Francisellatularensis
**	#	Vibrio species, including cholera	Vibrio species
**	Vaping-associated pulmonary illness7
*	Viral hemorrhagic fever	Arenaviruses and others
**	West nile	West nile virus
**	Western equine encephalitis	Western equine encephalitis virus
**	Yellow fever	Yellow fever virus
**	Zika virus disease	Zika virus
*	Any case of unusual illness of infectious cause
*	Any cluster/outbreak of illness with potential public health significance

¹ An illness with an onset of acute focal limb weakness and either 1) cerebrospinal fluid with an elevated white blood cell count or 2) a magnetic resonance image (MRI) showing a spinal cord lesion largely restricted to gray matter and spanning one or more spinal segments.

² Detection of Candida auris in a specimen using culture or culture independent diagnostic test; or detection of an organism that commonly represents a Candida auris misidentification.

³ Carbapenemase-producing carbapenem-resistant organisms are:

* Carbapenem-resistant organisms, as defined by the Clinical Laboratory Standards Institute Performance Standards for Antimicrobial Susceptibility Testing M100 (http://www.clsi-m100.com), that test positive for Carbapenemase-producing by a phenotype method or for a known carbapenemase resistance mechanisms by a recognized test, as defined by the U.S. Centers for Disease Control and Prevention (https://wwwn.cdc.gov/nndss/conditions/carbapenemase-producing-carbapenem-resistant-enterobacteriaceae/case-definition/2018/).

* Reporting will include test method used, result, and where applicable, specific resistance mechanisms identified.

* Isolate submission is required for all carbapenem-producing carbapenem-resistant organisms. If phenotypic or resistance mechanism test results are not available for a carbapenem-resistant organism, then isolate submission of the carbapenem-resistant organism is required to determine carbapenemase-producing status.

⁴ All cases with clinical signs, symptoms or known exposure consistent with diagnosis of carbon monoxide poisoning, and/or: a carboxyhemoglobin (COHb) level equal to or above 5%.

⁵Any human immunodeficiency virus (HIV) test results, including:

* All reactive/repeatedly reactive initial HIV immunoassay results and all results (e.g. positive, negative, indeterminate) from all supplemental HIV immunoassays (HIV-1/2 antibody differentiation assay, HIV-1 Western blot, HIV-2 Western blot or HIV-1 Immunofluorescent assay);

* All HIV nucleic acid (RNA or DNA) detection tests (qualitative and quantitative), including tests on individual specimens for confirmation of nucleic acid amplification testing (NAAT) screening results;

* All CD4 lymphocyte counts and percentages, unless known to be ordered for a condition other than HIV;

* HIV genotypic resistance testing, nucleotide sequence results; and,

* Positive HIV detection tests (including, but not limited to culture, P24 antigen).

⁶ As defined by the most current Clinical Laboratory Standards Institute Performance Standards for Antimicrobial Susceptibility Testing M100 (http://www.clsi-m100.com).

⁷ Clinicians should report cases with onset on or after May 1, 2019, that meet the criteria of (1) a significant respiratory illness of unclear etiology and (2) a history of vaping.

Notes

C.M.R. 10, 144, ch. 258, app A